In Randomized Study of Patients with Localized Cancer and DVT, Low Molecular Weight Heparin found to offer Survival Advantage over Coumarin Derivatives
BERKELEY, CA (UroToday Inc.) - Without question, patients with cancer at a higher risk for thromboembolic events. Until very recently, the decision to place a patient with deep vein thrombosis (DVT) on coumarin or low molecular weight heparin was largely based on drug cost or patient convenience.
 | Written by Ricardo Sånchez-Ortiz, MD, a Contributing Editor with UroToday. |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810 UroToday International Journal Correspondence
Privacy Policy | © 2010 UroToday ® All Rights Reserved |
